Phase I pharmacokinetic study of chronomodulated dose-intensified combination of capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer

Cancer Chemotherapy and Pharmacology, 06/04/2012

Chronomodulated dose–intensified capecitabine in combination with oxaliplatin (XELOX) facilitates delivery of dose–intense treatment in metastatic colorectal cancer (mCRC) with a favorable therapeutic index that is promising.

Print Article Summary Cat 2 CME Report